impaired fat oxidation overweight
Conditions
Interventions
Pilot study: All subjects will be studied 2 times, with once infusions in the
proximal colon and once infusions in the distal colon in randomized order, each
with three different infusions in random
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Overweight/obese men (BMI>=25kg/m2
Exclusion criteria
Exclusion criteria: - Type 2 diabetes mellitus (defined as FPG >= 7.0 mmol/l) - Gastroenterological diseases or abdominal surgery - Cardiovascular diseases, cancer, liver or kidney malfunction, disease with a life expectancy shorter then 5 years - Abuse of products - Plans to lose weight or following of a hypocaloric diet - Regular supplementation of pre- or probiotic products, use of pre- or probiotics 3 months prior to the start of the study - Intensive exercise training more than three hours a week - Use of any medication that influences glucose or fat metabolism and inflammation (i.e. NSAIDs). - Regular use of laxative products - use of antibiotics 3 months prior to the start of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome parameters are fat oxidation and energy expenditure. The impact of site of administration of SCFA on fat oxidation and energy expenditure will be studied as well as the duration of effect. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Hormones that influence substrate and energy metabolism like Insulin, Glucagon, GLP-1, PYY, FIAF; - Circulating metabolites like Glucose, Free Fatty Acids, Triglycerides; - Inflammatory markers like TNF-a, IL-6, IL-1, Adipokines; - Faecal and plasma SCFA content (Faecal samples only in pilot study); - Indirect markers of insulin sensitivity like circulating insulin concentrations; - Appetite (VAS-scoring system). | — |
Countries
Netherlands
Outcome results
None listed